Moffitt study presented at #ASTRO24 shows promising results for treating aggressive prostate cancer with #immunotherapy. #MoffittASTRO24 ASTRO JM Bryant, MD bit.ly/3Y4QSym

The team having fun and sharing their work at #ASTRO24 Moffitt Cancer Center ASTRO 💪🏽🧬

At 2 years, the FFBR rate was 90.3% among patients who received nivolumab plus radiotherapy compared with a historical control rate of 75% (P = .025). #pcsm | ASTRO JM Bryant, MD cancernetwork.com/view/nivolumab…

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer JM Bryant, MD MoffittRadOnc ASTRO #pcsm #oncology #ASTRO24 onclive.com/view/nivolumab…

The addition of nivolumab to SOC was associated with an improvement in freedom from biochemical recurrence in patients with grade group 5 prostate cancer, according to data from a phase 2 study presented at #ASTRO24. | JM Bryant, MD #pcsm urologytimes.com/view/nivolumab…

Congratulations to Jacqueline Andreozzi, PhD, DABR on winning the ARRO educator of the year award, Justyn Nakashima, DO on winning the clinical award, and to JM Bryant, MD on winning the leadership award! 💪🏽💥Jessica Frakes Stephen Rosenberg, MD

Dr Eric Tseng from Sunnybrook Health Sciences Centre Radiation Oncology presenting the UNITED trial MR-Linac Consortium meeting in Singapore. Radiation exposure to normal brain can be minimized without compromising control for glioblastoma using online adaptive radiotherapy on the MR-Linac

🧬Urinary extracellular vesicle miRNAs to detect pancreatic cancer eClinicalMedicine – The Lancet Discovery Science ✅Sensitivity (training and test sets) All: 93.9% and 77.8% Stage I/IIA: 97% and 77.8% ✅Outperformed ca19-9 ⁉️A noninvasive urinary assay 👉doi.org/10.1016/j.ecli… The Lancet Oncology The Lancet

Utilizing the HARD technique for Unresected sarcomas showed a 2-fold increase in 3y LRC (96% v 48%), when compared to standard fractionated RT. Congrats to JM Bryant, MD for acceptance in Radiotherapy & Oncology. MoffittRadOnc Moffitt Cancer Center #greenjournal @RadiotherapyOn1 QuadShot News

As we enter the last week of pancreas cancer awareness month- I want to remind everyone that the status quo is NOT GOOD ENOUGH for our patients. The only way we will make any progress is to design (& fund!) patient-centered clinical trials. Here are some I'm excited about 🧵:

Congratulations to Arash Naghavi, JM Bryant, MD, et al. for their HARD work and creating innovative and sophisticated solutions for patients with unresected soft-tissue sarcoma! Hypofractionated accelerated radiation dose-painting (HARD) improves o... sciencedirect.com/science/articl…

Going HARD at Soft Tissue Sarcoma! thegreenjournal.com/article/S0167-…

Utilizing the HARD approach, we showed a 2 fold increase in 3y LC (96% vs 48%), along with a PFS benefit for non-metastatic patients! MoffittRadOnc Moffitt Cancer Center #GoHardAtSoftTissueSarcoma thegreenjournal.com/article/S0167-…

Is preoperative SRS an option for brain metastases undergoing resection? Proud to share the INTERNEO results- an international collaboration of neoadjuvant SRS Radiotherapy & Oncology ↘️ low rates of local recurrence, nodular LMD and radionecrosis (all <5% at 12 months) 🌍 Global

Patients can benefit from SBRT / PBT over TACE in HCC (ineligible for upfront surgery/transplant) ! 🚨 Local Control HR 0.16 (0.08, 0.34) 🚨 💥 PFS HR 0.37 (0.23, 0.60) 💥 OS RR 0.79 (0.51, 1.22) Toxicity RR 0.86 (0.31, 2.37)

Thank you so much to Dr. Einhorn for being our honored guest at Resident Research Day ! Congrats to all the residents and their great presentations ! MoffittRadOnc Moffitt Cancer Center Kosj Yamoah MD, PhD Jessica Frakes JM Bryant, MD Ruben J. Cruz, MD #radonc

This year, we received a record number of applications and interviewed an incredibly competitive group. We’re thrilled to announce our match class! #MatchDay2025 #RadOnc ⚡️☢️☀️🌊Sylvester Comprehensive Cancer Center Miller Medicine Henri R. Ford, MD, MHA, FACS, FRCS(Eng), FAAP Stephen D. Nimer, MD

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Congratulations to our graduating chief residents for passing their clinical boards!! 🎉💯 JM Bryant, MD Ruben J. Cruz, MD

Congratulations to our Graduating Medical and Physics Residents! (Dr. Bryant, Dr. Cruz-Chamorro and Dr. Koo). We are so proud of you and know you will go onto great things! JM Bryant, MD Ruben J. Cruz, MD Jessica Frakes Evan Wuthrick Kosj Yamoah MD, PhD MoffittRadOnc Moffitt Cancer Center #radonc